BAX vs REGN: Which is Better to Buy in 2026?

Side-by-side fundamental comparison based on AI analysis of SEC filings

AI Verdict

REGN has stronger fundamentals based on our AI analysis.

BAX
BAXTER INTERNATIONAL INC
C
84%
Confidence
VS
REGN
REGENERON PHARMACEUTICALS, INC.
A
80%
Confidence

BAX vs REGN Fundamental Comparison

Metric BAX REGN
Revenue $2.7B $3.6B
Net Income $-15.0M $727.2M
Net Margin -0.6% 20.2%
ROE -0.2% 2.3%
ROA -0.1% 1.8%
Current Ratio 1.85x 3.57x
Debt/Equity 1.56x 0.06x
EPS $-0.03 $6.75

Green = Better metric | Red = Weaker metric

View Full BAX Analysis →
View Full REGN Analysis →
Browse Sectors: Technology Healthcare Finance Energy Consumer Industrial
Stock Lists: Top Rated Undervalued Growth Dividend

You Might Also Compare

BAX vs AAPL REGN vs MSFT BAX vs GOOGL REGN vs AMZN

BAX vs REGN: Frequently Asked Questions

Is BAX or REGN the better stock in 2026?

Based on dual AI fundamental analysis (Claude and ChatGPT), REGN has stronger fundamentals. BAX is graded C (84% confidence) while REGN is graded A (80% confidence). This is not investment advice.

How does BAX compare to REGN fundamentally?

BAXTER INTERNATIONAL INC has ROE of -0.2% vs REGENERON PHARMACEUTICALS, INC.'s 2.3%. Net margins are -0.6% vs 20.2% respectively.

Which stock pays higher dividends, BAX or REGN?

BAX has a dividend yield of N/A or no dividend while REGN has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.

Should I invest in BAX or REGN for long term?

For long-term investing, consider that BAX has a C grade with 84% confidence, while REGN has a A grade with 80% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.

What do the AI models say about BAX vs REGN?

Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For BAX vs REGN, the AI consensus favors REGN based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.